11 results about "Anti histamines" patented technology

The first present invention relates to an ophthalmic composition for reducing eye dryness containing at least one selected from the group consisting of chondroitin sulfate and salts thereof which have a weight-average-molecular weight of 40,000 to 70,000. The second present invention relates to an ophthalmic composition containing at least one selected from the group consisting of chondroitin sulfate and salts thereof which have a weight-average-molecular weight of 40,000 to 70,000, and at least one selected from the group consisting of an antihistamine, a zinc salt, tetrahydrozoline and salts thereof, hydroxyethyl cellulose and salts thereof, and a polyvinyl-based polymer compound. The third present invention relates to an ophthalmic composition containing at least one selected from the group consisting of chondroitin sulfate and salts thereof which have a weight-average-molecular weight of 40,000 to 70,000, and menthol.

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of guaifenesin, naproxen and at least one further active which is selected to be an antitussive, a decongestant or an antihistamine.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a compound in preparation of an anti-allergic medicine. The degranulation inhibition effect is verified through a mast cell in-vitro culture model, the overall anti-allergic activity is verified by combining an animal allergy model, and a series of experiments prove that the compound A33 can inhibit I-type anaphylaxis (such as ear and subcutaneous anaphylaxis) mediated by an IgE antibody. Different from a traditional anti-allergic drug (such as an antihistamine drug), the compound A33 is used for preventing release of media such as TNF-alpha and IL-6 from the source in an anaphylactic reaction starting link that the compound A33 directly inhibits mast cell degranulation in allusion to downstream blocking of an allergic medium, so that the compound A33 is introduced into the field of anti-allergic product research; a new candidate strategy with a clear targeting mechanism and an experimental basis is provided for prevention and / or treatment of allergic diseases, and the application value in anti-allergic drugs, cosmetics or daily chemical products is wide.

The present invention relates to the medical device and pharmaceutical industry, as well as related fields such as dermatology and cosmetics, since the formulation includes natural anti-inflammatory components and high viscous solvents such as polysorbate and glycerol, which work synergistically to enhance drug retention on the eye surface, minimize visual blur on instillation and reduce dosage frequency. The present invention describes a topical delivery of a cannabinoid-based ophthalmic composition that includes Tetrahydrocannabinol (THC)-based molecule isolated or associated with Cannabidiol (CBD). In another embodiment of the preferred invention, the formulation further comprises one or more synergistic agents, including but not limited to steroidal and non-steroidal anti-inflammatory and antihistamines pharmaceutical formulations.

The present invention provides a topical pharmaceutical composition that contains a nonsteroidal anti-inflammatory drug, a lower alcohol, vitamin E derivatives, and water, without the harmful effects caused by high concentrations of alcohol, and without suppressing the precipitation of insoluble substances. [Solution] The topical pharmaceutical composition of the present invention contains (A) a nonsteroidal anti-inflammatory drug, (B) a nonionic surfactant with an HLB value greater than 6.5, (C) 30-45% by weight of a lower alcohol, (D) an antihistamine, (E) 0.1-2% by weight of vitamin E derivatives, (F) 3-6% by weight of monoterpenes, and (G) water.

The invention relates to the technical field of traditional Chinese medicine liquid, in particular to traditional Chinese medicine liquid for treating eczema and pruritus, which is prepared from the following components in parts by weight: 2 parts of rhizoma coptidis, 5 parts of radix scutellariae and 2.7 parts of lucid ganoderma. In the traditional Chinese medicine liquid, the coptis chinensis can clear heat and dry dampness, the scutellaria baicalensis can purge fire and detoxify, the lucid ganoderma can support the healthy energy, the three medicines are synergistic, multiple mechanisms such as anti-inflammation, anti-allergy and immunity regulation are considered, the limitation of a single target of a chemical medicine is broken, the side effects such as skin atrophy and angiotelectasis of hormone medicines are completely avoided, and the traditional Chinese medicine liquid is suitable for long-term safe use; the medicinal materials are crushed to 200 meshes or above, a dynamic decoction tank and high-temperature extraction are matched, the dissolution rate of anti-inflammatory components such as berberine and baicalin in coptis chinensis is remarkably increased, compared with traditional Chinese medicines, the concentration of effective components is increased, pruritus can be relieved within 30 minutes, the effect taking speed of the traditional Chinese medicine liquid is close to that of chemical medicines, and the traditional Chinese medicine liquid is different from chemical antihistamine medicines, does not contain sedative components and is free of toxic and side effects. The liquid soap can be used for special people for driving and operating machinery, and has no irritation to damaged skin.

To provide an ophthalmic composition for reducing friction in an eye part.SOLUTION: An ophthalmic composition for contact lenses contains polyvinyl pyrrolidone with a K value of 40 or more (A), trometamol (B), and at least one selected from the group consisting of chondroitin sulfate, hyaluronic acid and salts thereof (C), with the content of the component (A) of 0.003-0.3 w / v%, and a pH of 6.5-7.5, excluding the following compositions (i) and (ii): (i) an ophthalmologic composition for soft contact lenses comprising antihistamine, glycyrrhizinic acid and / or a salt thereof, chondroitin sulfate and / or a salt thereof, and 0.5 w / v% or more of polyvinyl pyrrolidone, with a pH of 5.5-6.8; and (ii) a composition for contact lens cleaning comprising (A) a polyvinyl water-soluble polymer compound and (B) a compound selected from mucopolysaccharide, mucopolysaccharide salt, polyphosphoric acid and polyphosphate).SELECTED DRAWING: None

The application discloses a potent non-sleepy antiemetic and anti-motion sickness pharmaceutical composition and application thereof, and belongs to the technical field of medicines.The composition comprises five active ingredients of pheniramine maleate, caffeine, vitamin B6, scopolamine and lidocaine.Through the synergistic effect of the components, the composition can strongly inhibit the dizziness and vomiting reaction caused by the vestibular stimulation, and meanwhile, the sedative effect of the antihistamine drug is antagonized by caffeine, so that the side effect of sleepiness of the traditional anti-motion sickness drug is avoided while the anti-motion effect is ensured.Experiments show that the effect of the composition in an anti-motion sickness animal model is obviously better than that of each single drug and a conventional positive control drug.The composition can be used for preparing various pharmaceutical preparations for preventing and treating motion sicknesses such as car sickness, ship sickness and aircraft sickness, and has important clinical application value.

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of guaifenesin, naproxen and at least one further active which is selected to be an antitussive, a decongestant or an antihistamine.

The application discloses a compound solid preparation containing phenylephrine hydrochloride and a preparation method thereof, which is a solid preparation prepared by taking phenylephrine hydrochloride, acetaminophen and chlorpheniramine maleate as active ingredients, and taking a coating agent, a binder, a filler, a lubricant and the like as auxiliary materials, and the solid preparation is a tablet. Since phenylephrine hydrochloride can be degraded in the presence of oxygen, aldehyde, certain acids and metals, the phenylephrine hydrochloride is coated with a coating agent, and then mixed with other raw and auxiliary materials to prepare granules by using a dry granulation method, and finally, the granules are compressed to obtain the tablet.

Embodiments of the present disclosure generally relate to combination therapies and methods for myelin growth and / or remyelination. Embodiments described herein also relate to such combination therapies and methods used for the treatment of various diseases or medical conditions, such as age-related hearing loss, in a patient. In an embodiment, a combination therapy for stimulating remyelination of a neuron in a patient having hearing loss is provided. The combination therapy includes a pharmaceutical or pharmaceutical composition, the pharmaceutical or pharmaceutical composition comprising an antihistamine, a remyelination therapy, a therapy prescribed for treatment of multiple sclerosis, or combinations thereof. The combination therapy further includes an audio file configured to facilitate remyelination of a neuron upon administration of the pharmaceutical or pharmaceutical composition.